Accelerate Diagnostics
AXDX
AXDX was delisted on the 14th of May, 2025.
116 hedge funds and large institutions have $551M invested in Accelerate Diagnostics in 2018 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 35 increasing their positions, 34 reducing their positions, and 11 closing their positions.
47% more call options, than puts
Call options by funds: $23.5M | Put options by funds: $15.9M
3% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 34
0% more funds holding
Funds holding: 116 → 116 (0)
0% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 11
6% less capital invested
Capital invested by funds: $584M → $551M (-$32.6M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Chicago Capital
Chicago,
Illinois
|
+$5.58M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$5.38M |
| 3 |
CWG
C WorldWide Group
Copenhagen,
Denmark
|
+$4.12M |
| 4 |
AAMU
Amundi Asset Management US
Boston,
Massachusetts
|
+$3.23M |
| 5 |
NCGI
Next Century Growth Investors
Plymouth,
Minnesota
|
+$1.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
-$10.4M |
| 2 |
KCM
Kornitzer Capital Management
Shawnee Mission,
Kansas
|
-$10.1M |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$8.92M |
| 4 |
MGM
Miura Global Management
New York
|
-$4.57M |
| 5 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
-$3.88M |
AXDX Hedge Fund Activity: Q2 2018 in Review
116 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Accelerate Diagnostics (AXDX) for Q2 2018, worth a combined $551M — down 5.6% from $584M a quarter earlier.
Fund positioning in AXDX was balanced in Q2 2018: 11 funds opened new positions, 11 closed out, 35 added to existing stakes and 34 trimmed.
The largest buyer was Chicago Capital, adding an estimated $5.58M. The largest seller was Loomis, Sayles & Company, exiting entirely with an estimated $10.4M sold.
- 116 institutional investors held Accelerate Diagnostics (AXDX) as of Q2 2018, unchanged from Q1 2018.
- Funds reported $551M of Accelerate Diagnostics stock for Q2 2018, down 5.6% quarter-over-quarter.
- 11 funds opened new Accelerate Diagnostics positions in Q2 2018 and 11 closed out, a net change of 0 holders.
- The largest Accelerate Diagnostics buyer in Q2 2018 was Chicago Capital, an estimated $5.58M added.
- The largest Accelerate Diagnostics seller in Q2 2018 was Loomis, Sayles & Company, an estimated $10.4M sold.
Based on aggregated 13F filings for Q2 2018.